56.Issue 05 may 22 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 09, Issue : 05, May – 2022

Title:

56.COMPARISON BETWEEN USFDA AND EU REGULATORY MARKETS IN PHARMACEUTICALS
‬

Authors :

Shitole A R*, Adsul T D, Durande S L, Shinde D B

Abstract :

Regulatory Affairs in the pharmaceutical business is coping with all aspects of state affairs and to fulfil the wants of the company administrative body of the involved nations and deals with getting the approval from the license, development of a pharmaceutical product to production, drug approval method and registration of pharmaceutical merchandise available and distribution in numerous regulated markets and for post promoting studies. The pharmaceutical firms should obey the legislations that need medicine to be developed, tested, trailed, and made in accordance with the rules in order that they’re safe and their well-being is protected. The FDA regulates medical pharmaceuticals and devices with competing aims of ensuring safety and efficacy while also allowing novel therapies to advance quickly through the investigation and regulatory processes. The United States and the European Union take different approaches to these issues. The European Commission synchronised the legislation of 28 distinct countries as they merged to form the European Union, but the United States has always depended on a strictly centralised method through one agency, the Food and Drug Administration (FDA). The FDA began as a consumer protection body, but the European Commission’s laws evolved from a desire to reconcile inter-state commercial interests while maintaining national “autonomy.”
Key words: Regulatory Affairs, drug approval, pharmaceutical Industry, USFDA, EU regulatory markets.

Cite This Article:

Please cite this article in press Shitole A R et al, Extraction, Comparison Between USFDA & EU Regulatory Markets In Pharmaceuticals., Indo Am. J. P. Sci, 2022; 09(5).,

Number of Downloads : 10

References:

1. Raji K, Aanandhi VM. Regulatory Filing In Us and Eu: A Comparative View. Res J Pharm and Tech. 2017;10(1):286-92.
2. Kashyap UN, Gupta V, Raghunandan HV. Comparison of drug approval process in United States & Europe. J Pharm Sci and Res. 2013 Jun 1;5(6):131.
3. Raji K, Aanandhi VM. Regulatory Filing In Us and Eu: A Comparative View. Res J Pharm and Tech. 2017;10(1):286-92.
4. Health Canada. (2011, March 29). Guidance for industry: Management of drug submissions.RetrievedJuly 18, 2012, from http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applicdemande/ guide-ld./mgmt.-gest/mands_gespd-eng.php#a5.2.
5. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 201.
6. IRA R Berry, Robert P Martin, editors. The Pharmaceutical Regulatory Process. 2nd ed. Informa healthcare. p.48.
7. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley and Sons, Inc., (Hoboken, New Jersey). p. 212-14.
8. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley and Sons, Inc., (Hoboken, New Jersey). p. 215-17.
9. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 203-4.
10. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 205-7.
11. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 208-10.
12. IRA R Berry, Robert P Martin, editors. The Pharmaceutical Regulatory Process. 2nd ed. Informa healthcare. p. 46.
13. Rick NG. Drugs from discovery to approval. 2nd ed. John Wiley & Sons, Inc., (Hoboken, New Jersey). p. 212-14.
14. Singh Satbir, Kumar Pankaj, and Rana Arpana, Global Regulatory Challenges of Common Technical Document, World Journal of Pharmacy and Pharmaceutical Sciences, Vol.6, Issue 12, 2017.
15. Sharma D, Sharma V, Shrivastava B and Songara R, “Comparative study of dossier files submission process for drug product in United states and Europe”, Pharmacology online, 2011; 2: 337-362.
16. Bhalodiya HA, Boda JM, Shah JS, Patel PB and Vaghela JP, “The Common Technical Document: Taking Indian NDA process towards globalization”, International Journal of pharmaceutical Science Review and Research, 2011; 30: 181-187.
17. Sharma D, Sharma V, Shrivastava B and Songara R, “Comparative study of dossier files submission process for drug product in United states and Europe”, Pharmacology online, 2011; 2: 337-362.
18. Nisar Ahammad, Nagarjuna Reddy, M.V. Nagabhushanam, Brahmaiah Ramakrishna, Challenges faced during eCTD and CTD filing Procedures for USFDA and Canada, Journal of Drug Delivery and Therapeutics, 2019.
19. Joseph Lincy, George Mathew, Malaviya Kalpesh K, Chalco Bincy, Badjatya Jitendra K, Comparative Study for Generic drug approval process and their registration as per CTD in Europe, USA, and Brazil, International Journal of Drug Regulatory Affairs, 2016.
20. Mulaje SS, Birajdar S M, Patil B R, Bhusnure OG, Procedure for Drug approval in Different countries: A review, Journal of Drug Delivery and Therapeutics, 2011.
21. Indu Gurram, M.V.S. Kavitha, Nagarjuna Reddy, M V Nagabhushanam, Drug Master Filing in US, Europe, Canada and Australia, Review Article, Journal of Pharmaceutical Research, Vol.16, Issue 2, Apr-Jun, 2017.
22. Bhardwaj S, Budhwar V and Gupta VK, “Comparative study: Requirements for the submission of generic drug application across US & EU in CTD/eCTD format”, Asian Journal of Pharmaceutical Science and Research, 2011; 1: 1-13.
23. Songara R, Shrivastava B, Sharma D and Sharma V, “Comparative study of dossier files submission process for drug product in United states and Europe”, International Journal of Pharmaceutical Research and Development, 2011; 3: 60-78.
24. Holbein ME, “Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators”, Journal of investigative medicine, 2009; 57: 689-695
25. Chavan PN, Vijayan S, Joshi MM, Godse N, Marialouis J, Kasibhatta R. Marketing authorisation procedures in Europe: A Regulatory perspective. International Journal of Pharmacy & Pharmaceutical Science Research. 2011; 1(1):13-19.
26. Ellender D, Marangoni E. EFPIA workshop: The 2001 review of European Union Pharmaceutical
27. Legislation. International Journal of Pharmaceutical Medicines. 2001; 15(3):140-9.
28. Nordfield K, Strasberger V. Creating eCTD applications. Journal of generic Medicines. 2006; 3(2):140-6.
29. Teresa M, Miguel S, Vagas E. Drug evaluation and approval process in the European Union. 2006;55(1):12-14.
30. U.S. Food and Drug Administration. (2005, April). Guidance for Review Staff and Industry. Good Review Management Principles and Practices for PDUFA Products. Retrieved July18,2012, fromhttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm079748.pdf.
31. Grignolo, A. (2008). Meeting with the FDA. In Pisano, D.J. and Mantus, D.S. (Eds.) FDA regulatory affairs: A guide for prescription drugs, medical devices, and biologics (2nd ed., pp.109-23). New York: Informa Healthcare.
32. European Medicines Agency. (2012, April). European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure. Retrieved September 26, 2012,http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004069.pdf.
33. Sahoo U and Kumar N, The Regulatory Affairs Profession in India, The Regulatory Affairs Journal –Pharma, 2007, 19(1), 25-28.
34. Guidelines for Drug Master Files [Internet]. CDER, FDA; 2005 Mar [cited 2015 Nov 15]. Availablefrom:http://www.FDA.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122886.htm (Accessed on 15th march 2017).
35. Dylst P, Vulto A, Simoens S. Overcoming challenges in market access of generic medicines in the European Union. Journal of Generic Medicines. 2012;9(1):21-8.
36. “Generic Drugs”, U.S. Food and Drug Administration. Available from: http://en.wikipedia.org/wiki/U.S._Food_and_Drug_Administration [accessed23.11.2017.
37. Rahul R, et al. Comparative Study of Generic Drug Approval in EU, USA and China. Int J Pharm Sci Rev Res. 2017;42(2):67-73.
38. Ramana MV, et al. Generic Drug Registration Procedure in US and European Markets. Am J Pharm Health Res. 2014;2(11):12-21.
39. Siddharth NS, Pethani T and Sheth NR. A review on comparison of regulatory requirements to approved drug device combination products in Europe and USA. World J Pharm Pharm Sci 2014; 3: 455–475.
40. Vihar K. Regulatory strategy for registration of combination products to us-FDA. International Journal of Drug Regulatory Affairs 2014; 2: 27–42.
41. Hirako M, McAuslane N, Salek S, Anderson C, Walker S. A comparison of the drug review process at five international regulatory agencies. Drug Inf J 2007;41: 291-308.
42. PanteliD, Arickx F, Cleemput I, et al. Pharmaceutical Regulation in 15 European Countries: Review. Geneva, Switzerland: Word Health Organization; 2016.